Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 15NET 3Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 2646Lymphoma, T-Cell, Cutaneous 479Skin Neoplasms 408Carcinoma, Non-Small-Cell Lung 377Mycosis Fungoides 330Neoplasms 319Keratosis, Actinic 300Sezary Syndrome 294Breast Neoplasms 285Neoplasm Metastasis 284Carcinoma, Renal Cell 280Lymphoma, Non-Hodgkin 276Lymphoma 263Carcinoma, Basal Cell 262Lymphoma, Large B-Cell, Diffuse 261Leukemia, Lymphocytic, Chronic, B-Cell 261Lymphoma, Follicular 259Hodgkin Disease 247Lymphoma, Mantle-Cell 245Lymphoma, B-Cell, Marginal Zone 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 243Uveal Melanoma 234Burkitt Lymphoma 233Lymphoma, Large-Cell, Immunoblastic 223Colorectal Neoplasms 196Lymphoma, Large-Cell, Anaplastic 190Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 186Ovarian Neoplasms 181Squamous Cell Carcinoma of Head and Neck 180Lung Neoplasms 179

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Acromegaly × Dermatologic × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡